| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 06/13/2002 | WO2002046458A2 Nucleic acids of the human abca5, abca6, abca9, and abca10 genes, vectors containing such nucleic acids and uses thereof |
| 06/13/2002 | WO2002046423A2 Protein derived from the melanin-concentrating hormone (mch), corresponding nucleic acids and their use for preparing medicines |
| 06/13/2002 | WO2002046419A2 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| 06/13/2002 | WO2002046418A2 Lipid-associated molecules |
| 06/13/2002 | WO2002046412A2 Regulation of angiogenesis with zinc finger proteins |
| 06/13/2002 | WO2002046409A2 Proteins and nucleic acids encoding same |
| 06/13/2002 | WO2002046404A2 Schizophrenia-related voltage-gated ion channel gene and protein |
| 06/13/2002 | WO2002046401A1 Use of cells derived from embryonic stem cells for increasing transplantation tolerance and for repairing damaged tissue |
| 06/13/2002 | WO2002046386A2 Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase |
| 06/13/2002 | WO2002046385A2 Enzymes |
| 06/13/2002 | WO2002046384A2 Kinases and phosphatases sequences, and use thereof |
| 06/13/2002 | WO2002046383A2 Protein modification and maintenance molecules |
| 06/13/2002 | WO2002046373A1 Method of collecting placental stem cells |
| 06/13/2002 | WO2002046239A1 Thermoplastic and water soluble cellulose ether esters |
| 06/13/2002 | WO2002046230A2 G-protein coupled receptors |
| 06/13/2002 | WO2002046225A2 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 06/13/2002 | WO2002046220A2 Sequences upstream of the carp gene, vectors containing them and uses thereof |
| 06/13/2002 | WO2002046216A2 Human sprouty-4 polypeptide |
| 06/13/2002 | WO2002046214A2 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 06/13/2002 | WO2002046197A1 Macroheterocylic compounds useful as kinase inhibitors |
| 06/13/2002 | WO2002046184A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 06/13/2002 | WO2002046183A2 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 06/13/2002 | WO2002046182A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors |
| 06/13/2002 | WO2002046181A2 Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 06/13/2002 | WO2002046174A1 1, 2, 4-oxadiazole derivatives as hppar alpha agonists |
| 06/13/2002 | WO2002046172A2 Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 06/13/2002 | WO2002046171A2 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 06/13/2002 | WO2002046170A2 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 06/13/2002 | WO2002046169A1 Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors |
| 06/13/2002 | WO2002046168A1 Therapeutic benzimidazole compounds |
| 06/13/2002 | WO2002046167A1 Benzyl (idene)-lactams and their use as 5ht1-receptor ligands |
| 06/13/2002 | WO2002046166A1 Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
| 06/13/2002 | WO2002046164A1 Therapeutic compounds |
| 06/13/2002 | WO2002046162A1 Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors |
| 06/13/2002 | WO2002046161A1 Substituted carboxylic acid derivatives |
| 06/13/2002 | WO2002046158A2 Piperidine/piperazine-type inhibitors of p38 kinase |
| 06/13/2002 | WO2002046154A1 Peroxisome proliferator activated receptor d activators |
| 06/13/2002 | WO2002046148A1 Substituted anthranilic acids |
| 06/13/2002 | WO2002046147A2 Perturbed membrane-binding compounds |
| 06/13/2002 | WO2002046146A1 Substituted carboxylic acid derivatives |
| 06/13/2002 | WO2002046141A2 Coumpounds of the formula r1-x-y-z-nr2r3 as abca-1 elevating agents against coronary artery disease or atherosclerosis |
| 06/13/2002 | WO2002046134A1 Novel estrogen receptor ligands and methods iii |
| 06/13/2002 | WO2002045737A2 Methods of treatment involving human mda-7 |
| 06/13/2002 | WO2002045716A1 Use of pyrazolo[4,3-d]pyrimidines |
| 06/13/2002 | WO2002045705A2 Regenaration of blood vessels |
| 06/13/2002 | WO2002045702A2 Tricyclic therapeutics for chemokine mediated diseases |
| 06/13/2002 | WO2002045695A2 Hydrostatic delivery system for controlled delivery of agent |
| 06/13/2002 | WO2002028825A3 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl- substituted phenyl acetamides as protease inhibitors |
| 06/13/2002 | WO2002026929A3 Kini-3 motor protein and methods for its use |
| 06/13/2002 | WO2002017857A3 Methods and compositions for inhibiting angiogenesis |
| 06/13/2002 | WO2002015891A3 Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors |
| 06/13/2002 | WO2002014357A3 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 06/13/2002 | WO2002008222A3 HETEROARYL-β-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS |
| 06/13/2002 | WO2002008219A3 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 06/13/2002 | WO2002003962A3 Drug delivery system for poorly water soluble drugs |
| 06/13/2002 | WO2002000657A3 Condensed pyrazindione derivatives |
| 06/13/2002 | WO2001096330A3 Thrombin receptor antagonists |
| 06/13/2002 | WO2001094547A3 Molecular delivery vehicle for delivery of selected compounds to targets |
| 06/13/2002 | WO2001094415A3 Nuclear hormone receptor |
| 06/13/2002 | WO2001090104A3 -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases |
| 06/13/2002 | WO2001089554A3 Treatment of acute coronary syndrome with glp-1 |
| 06/13/2002 | WO2001085145A3 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| 06/13/2002 | WO2001079170A3 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof |
| 06/13/2002 | WO2001077057A3 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
| 06/13/2002 | WO2001072309A3 Treatment of cerebrovascular disease |
| 06/13/2002 | WO2001070233A3 Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof |
| 06/13/2002 | WO2001059103A3 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression |
| 06/13/2002 | WO2001044300A3 Brain specific binding members |
| 06/13/2002 | WO2001037819A3 Use of indirubine derivatives for making medicines |
| 06/13/2002 | WO2000064400A9 Methods for treating congestive heart failure |
| 06/13/2002 | WO1999059957A9 Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase |
| 06/13/2002 | US20020072631 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 06/13/2002 | US20020072630 Therapy |
| 06/13/2002 | US20020072614 For therapy of cardiovascular, cerebrovascular, respiratory and renal disorders |
| 06/13/2002 | US20020072609 Process for preparing arylacetylaminothiazoles |
| 06/13/2002 | US20020072540 For therapy, prophylaxis and diagnosis of respiratory distress syndrome or other pulmonary diseases that are associated with deficiency of lung surfactant |
| 06/13/2002 | US20020072539 For therapy of tumor necrosis factor(TNF), edema, neurological deficits, stroke and for therapy of pathological conditions caused by TNF-alpha |
| 06/13/2002 | US20020072534 20- Hete antagonists and agonists |
| 06/13/2002 | US20020072529 For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma |
| 06/13/2002 | US20020072526 Orally active salts with tyrosine kinase activity |
| 06/13/2002 | US20020072525 Aryl fused azapolycyclic compounds |
| 06/13/2002 | US20020072524 Aryl fused azapolycyclic compounds |
| 06/13/2002 | US20020072520 For use in therapy of hyperlipidemia and arteriosclerotic disorders |
| 06/13/2002 | US20020072518 Bicyclic alphavbeta3 antagonists |
| 06/13/2002 | US20020072517 Substituted cyclic amine metalloprotease inhibitors |
| 06/13/2002 | US20020072515 For therapy and prophylaxis of ischemic heart diseases such as angina pectoris, arrhythmia, myocardial infarction, congestive heart failure, cerebral infarction and cerebral sequelae after subarachnoid hemorrhage, hypertension |
| 06/13/2002 | US20020072514 For use in prophylaxis and therapy of cardiovascular disorders, in particular arrhythmias, for treatment of prophylaxis and therapy of cardiovascular disorders, in particular arrhythmias, for therapy of diarrheal disorders |
| 06/13/2002 | US20020072511 Apparatus and method for delivering compounds to a living organism |
| 06/13/2002 | US20020072510 3-nitrogen-6,7-dioxygen steroids and uses related thereto |
| 06/13/2002 | US20020072500 3-(carboxy(hydroxy)alkylaminocarbonylmethylaminocarbonyl), 5-(tetrahydropyrimidin-2-yl-amino)phenol for example |
| 06/13/2002 | US20020072499 Specifically an N-formyl-methionyl-leucyl ("f-Met-Leu") tri-or tetra-peptide; pathological fibrosis or those caused by trauma or surgery |
| 06/13/2002 | US20020072494 Angiogenesis inhibitor, K1-5 (protease-activated kringles 1-5) genetically engineered so it can be secreted from cells in which it is expressed; contains a secretory signal peptide and a pre-activation peptide derived from plasminogen |
| 06/13/2002 | US20020072491 Homology to members of the myosin light chain kinase subfamily |
| 06/13/2002 | US20020072489 Fibroblast growth factors (FGF); single unit dosage; treating coronary artery disease (atherosclerosis) |
| 06/13/2002 | US20020072485 Administering prior to the impairment of glucose and/or oxygen to the brain an NMDA receptor subunit (NR2B) selective NMDA antagonist to inhibit neuronal damage (ischemia) |
| 06/13/2002 | US20020072101 Novel human nucleic acid molecules and polypeptides encoding cation channels |
| 06/13/2002 | US20020072073 Joining liver receptors to solid support; generate solid support, join aniline derivative to support, incubate with aldehye, ketone, incubate aniline derivative with acylating agent, recover support |
| 06/13/2002 | DE10061334A1 Verwendung von aus embryonalen Stammzellen hergeleiteten Zellen zur Erhöhung der Transplantationstoleranz und zur Wiederherstellung zerstörten Gewebes Using derived from embryonic stem cells to increase transplant tolerance and restore damaged tissue |
| 06/13/2002 | CA2678490A1 Isolated placental perfusate and placental cells isolated therefrom |
| 06/13/2002 | CA2436916A1 Use of pyrazolo[4,3-d]pyrimidines |